Amy Langer on Leave of Absence From NABCO After Automobile Accident

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

NEW YORK--Amy S. Langer, of the National Alliance of Breast Cancer Organizations (NABCO), has taken a leave of absence from her position as executive director, due to extensive injuries suffered in a serious car accident in upstate New York.

NEW YORK--Amy S. Langer, of the National Alliance of Breast CancerOrganizations (NABCO), has taken a leave of absence from her positionas executive director, due to extensive injuries suffered in aserious car accident in upstate New York.

The NABCO Board of Directors said in a press release that Ms.Langer is expected to recover sufficiently to return to NABCOonce her treatment and rehabilitation have concluded. During thisperiod, Betsy Gardella, NABCO's associate executive director,will assume Ms. Langer's responsibilities as acting executivedirector.

The members of NABCO's board "are deeply saddened by theaccident and express their support to Ms. Langer and her family."The staff of Oncology News International and everyone at PRR,Inc. also wish to convey their concern for Ms. Langer and offertheir support and prayers for her and her family.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content